Koki Fukazu

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001.

The Children's Mercy Hospital provides pediatric health care services. It offers abdominal pain program, adolescent medicine, anesthesiology, bioethics, bone marrow transplantation, burn and trauma care, cardiology, child abuse and neglect, cleft palate and craniofacial, dentistry, dermatology, down syndrome clinic, eating disorders center, endocrinology and diabetes, epilepsy center, fetal health center, gastroenterology, genetics, gynecology, hand clinic and surgery, hematology, heart center, imaging, kidney and liver transplant, medical imaging, neonatology, neurology, nutrition services, ophthalmology, pain management, pathology and laboratory medicine, pharmacology, radiology, respiratory care, sexual differentiation treatment, sleep disorders program, surgery, telemedicine, urgent care, urologic surgery, and weight management services. The company was founded in June 1897 and is headquartered in Kansas City, MO.

Part of Bayer AG, Monsanto Japan Ltd. is a Japanese company that manufactures a wide range of genetically altered seeds, fertilizers, and agrochemicals. The company is based in Tokyo, Japan.

Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California.

Life Science Management, Inc. provides consulting services for businesses in the life science and healthcare industries. The Japanese company's focus is on helping these businesses to succeed and grow.

AccuRna, Inc. researches and develops nucleic acid-based drugs using drug delivery system technologies. The company was founded on December 18, 2015 and is headquartered in Tokyo, Japan.

HanaVax, Inc. develops nasal vaccine against infectious diseases. It develops pneumococcal nasal vaccine to prevent pneumonia, sepsis and otitis media. The company was founded by Hosei Ou on December 27, 2017 and is headquartered in Tokyo, Japan.

NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom.

Braizon Therapeutics, Inc. is a Japanese company that engages in researching and developing drugs. The company was founded in 2015 by Mariko Tosu. The CEO is Bunichi Wanibuchi.

Modulus Discovery, Inc. preclinical stage drug Discovery Company. It is focused on rapid design and generation of small molecule clinical candidates for disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The company was founded by Shun Roy Kimura And Kazuki Ohno and is headquartered in Minato-ku, Japan.

Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site."

PuREC KK is a company based in Japan that aims to revolutionize the future of regenerative medicine by developing a high-purity mesenchymal stem cell culture technology called REC (Rapidly Expanding Cell). REC has approximately 1000 times more pharmacological efficacy in terms of proliferation and differentiation compared to normal mesenchymal stem cells, making it effective in treating a wide range of diseases. The Japanese company was founded in 2016 by Shotai Kobayashi.

Metagen Therapeutics, Inc. is a company based in Tsuruoka, Japan. The Japanese company was founded in 2020 by Taku Nakahara, Takuji Yamada, Shinji Fukuda, and Dai Ishikawa. Taku Nakahara has been the CEO since 2020.

Sonire Therapeutics, Inc. (TY) is a company based in Tokyo, Japan. The Japanese company specializes in developing a next-generation ultrasonic guide ultrasonic ultrasonic treatment device using acoustic engineering (ultrasonic) technology created from academia, which conducts cutting-edge research. The device uses high-intensity focused ultrasound (HIFU) and is designed to be used under ultrasonic guidance. The company was founded in 2020 and the CEO is Toru Sato.